Augusta Researcher Wins $3.8M Grant for Heart Study

Kunzhe Dong will use a five-year National Institutes of Health grant to study a molecule linked to atherosclerosis.

Updated on Nov. 16, 2026 in Heart Disease

Isometric editorial illustration of plain glass vials and coiled tubing on a bench beside an arterial cross-section, in oxblood, teal, and mustard.
Augusta researcher Kunzhe Dong won a five-year, $3.8 million National Institutes of Health grant to study how the molecule PRDM16-DT drives atherosclerosis. AI Illustration. Upload story photo >

Live Poll

Do you trust federally funded medical research to improve heart health?

Kunzhe Dong, an assistant professor with the Immunology Center of Georgia and the Medical College of Georgia, received a five-year, $3.8 million grant from the National Institutes of Health. The funding supports research into how a molecule called PRDM16-DT affects atherosclerosis, the buildup of cholesterol and other substances inside artery walls.

Why it matters

Atherosclerosis can lead to blood clots from ruptured plaques that may cause heart attacks and strokes, making it a major driver of cardiovascular disease. Dong hopes the work will identify a new therapeutic target for treating and preventing the condition.

The grant is a $3.8 million, five-year National Institutes of Health award, and the molecule PRDM16-DT is found at high levels in healthy blood vessels and smooth muscle cells. Whether genetic variants alter its expression, and whether it can be targeted therapeutically, remains to be determined.

The players

Kunzhe Dong

Dong is an assistant professor with the Immunology Center of Georgia and the Medical College of Georgia, leading research into vascular disease mechanisms.

National Institutes of Health

The NIH is the principal federal agency funding biomedical and health research in the United States.

Augusta University

Augusta University is the institution that houses the Medical College of Georgia and the Immunology Center of Georgia.

The details

Dong will investigate how PRDM16-DT regulates smooth muscle cells during atherosclerosis and examine how genetic variants affect the RNA's expression. PRDM16-DT is a long noncoding RNA, a type of molecule that does not code for proteins but can regulate gene activity.

Timeline

  1. Five-year grant funding period for the research.

  2. Grant announcement published November 16, 2026.

Roadmap

Federal grants from the National Institutes of Health have long funded investigations into atherosclerosis, the leading underlying cause of heart attacks and strokes. This award extends that line of inquiry toward noncoding RNA molecules as possible new targets for therapy.

The research is at an early stage and will not change treatment options soon. It aims to identify a target that could eventually lead to new ways to prevent or treat the buildup of plaque in arteries.

The takeaway

Atherosclerosis develops silently over years, so routine heart health checkups and managing cholesterol remain the most practical steps for reducing risk. New research like this builds the scientific base for future preventive treatments.

Further reading

Explore more on Heart Disease and related cardiovascular research coverage.

Source note: This article includes information reported by Augusta Chronicle.

Live Poll

Do you trust federally funded medical research to improve heart health?